Literature DB >> 11834722

Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins.

Anat David1, Nicola Mabjeesh, Idit Azar, Sharon Biton, Sharon Engel, Jeanne Bernstein, Jacob Romano, Yoav Avidor, Tova Waks, Zelig Eshhar, Salomon Z Langer, Beatriz Lifschitz-Mercer, Haim Matzkin, Galit Rotman, Amir Toporik, Kinneret Savitsky, Liat Mintz.   

Abstract

Prostate-specific antigen (PSA) and human kallikrein 2 are closely related products of the human kallikrein genes KLK3 and KLK2, respectively. Both PSA and human kallikrein 2 are produced and secreted in the prostate and have important applications in the diagnosis of prostate cancer. We report here the identification of unusual mRNA splice variants of the KLK2 and KLK3 genes that result from inclusion of intronic sequences adjacent to the first exon. The novel proteins encoded by these transcripts, named PSA-linked molecule (PSA-LM) and hK2-linked molecule (K-LM), share only the signal peptide with the original protein product of the respective gene. The mature proteins are entirely different and bear no similarity to the kallikrein family or to other proteins in the databases. As is the case with PSA, PSA-LM is expressed in the secretory epithelial cells of the prostate and is up-regulated in response to androgenic stimulation. A similar pattern of expression is suggested for K-LM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834722     DOI: 10.1074/jbc.M102285200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  An atlas of transposable element-derived alternative splicing in cancer.

Authors:  Evan A Clayton; Lavanya Rishishwar; Tzu-Chuan Huang; Saurabh Gulati; Dongjo Ban; John F McDonald; I King Jordan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-02-10       Impact factor: 6.237

2.  Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.

Authors:  Sophia Adamia; Tony Reiman; Mary Crainie; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

3.  Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.

Authors:  Kathryn L Penney; Fredrick R Schumacher; Peter Kraft; Lorelei A Mucci; Howard D Sesso; Jing Ma; Yuxin Niu; Jit Kong Cheong; David J Hunter; Meir J Stampfer; Stephen I Hsu
Journal:  Carcinogenesis       Date:  2011-03-18       Impact factor: 4.944

4.  Structural characterization and expression of five novel canine kallikrein-related peptidases in mammary cancer.

Authors:  Katerina Angelopoulou; George S Karagiannis
Journal:  Mamm Genome       Date:  2010-09-19       Impact factor: 2.957

5.  Evidence for the novel expression of human kallikrein-related peptidase 3, prostate-specific antigen, in the brain.

Authors:  Jeremy G Stone; Raj K Rolston; Masumi Ueda; Hyoung-Gon Lee; Sandy L Richardson; Rudy J Castellani; George Perry; Mark A Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-10-20

6.  A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Authors:  Sophia Adamia; Benjamin Haibe-Kains; Patrick M Pilarski; Michal Bar-Natan; Samuel Pevzner; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; John Burke; Ilene Galinsky; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Richard Stone; James D Griffin
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

7.  The canine kallikrein-related peptidases 9 and 10: structural characterization and expression in mammary cancer.

Authors:  Katerina Angelopoulou; George S Karagiannis
Journal:  Mamm Genome       Date:  2009-12-02       Impact factor: 2.957

8.  NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

Authors:  Sophia Adamia; Michal Bar-Natan; Benjamin Haibe-Kains; Patrick M Pilarski; Christian Bach; Samuel Pevzner; Teresa Calimeri; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; Ilene Galinsky; Steven Mathews; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Daniel G Tenen; Richard M Stone; James D Griffin
Journal:  Blood       Date:  2014-02-26       Impact factor: 22.113

9.  Autoantibody approach for serum-based detection of head and neck cancer.

Authors:  Ho-Sheng Lin; Harvinder S Talwar; Adi L Tarca; Alexei Ionan; Madhumita Chatterjee; Bin Ye; Jerzy Wojciechowski; Saroj Mohapatra; Marc D Basson; George H Yoo; Brian Peshek; Fulvio Lonardo; Chuan-Ju G Pan; Adam J Folbe; Sorin Draghici; Judith Abrams; Michael A Tainsky
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11       Impact factor: 4.254

10.  Serum prognostic biomarkers in head and neck cancer patients.

Authors:  Ho-Sheng Lin; Fauzia Siddiq; Harvinder S Talwar; Wei Chen; Calin Voichita; Sorin Draghici; Gerald Jeyapalan; Madhumita Chatterjee; Andrew Fribley; George H Yoo; Seema Sethi; Harold Kim; Ammar Sukari; Adam J Folbe; Michael A Tainsky
Journal:  Laryngoscope       Date:  2014-01-29       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.